Tumours with 6p21–p23 gain or amplification
| Type of tumour | Number of tumours | Tumours with gain in 6p21–p23 (%) | Tumours with amplification in 6p21–p23 (%) |
|---|---|---|---|
| *This site does not currently allow the determination of the level of imbalance in a subset of breast and colon carcinomas. | |||
| Summary of genomic imbalance datasets from Progenetix (http://www.progenetix.com). | |||
| Carcinomas* | |||
| Hepatocellular carcinoma | 409 | 22.61 | 0.20 |
| Merkel cell carcinoma | 48 | 27.10 | 2.10 |
| Basal cell carcinoma | 16 | 40.30 | 0.00 |
| Ovarian serous carcinoma | 56 | 28.60 | 0.00 |
| Transitional cell carcinoma | 133 | 9.68 | 0.51 |
| Lymphoid tumours | |||
| Large B cell lymphoma | 360 | 8.36 | 0.07 |
| Plasmacytoma | 21 | 22.76 | 0.00 |
| Sarcomas | |||
| Osteosarcoma | 137 | 33.19 | 3.39 |
| Malignant peripheral nerve sheath | 70 | 23.93 | 0.00 |
| Leiomyosarcoma | 136 | 9.98 | 1.64 |
| Melanomas | 91 | 31.78 | 0.00 |
| Retinoblastoma | 133 | 39.36 | 10.50 |
| Glioblastoma | 108 | 4.60 | 0.90 |
| Neuroblastoma | 303 | 22.10 | 0.17 |
| Carcinosarcoma | 23 | 21.70 | 6.31 |